COMP <GO>
VERU vs EDSA // FORWARD P/E MULTIPLE
Veru Inc. (NASDAQ) VS. Edesa Biotech Inc. (NASDAQ) • 15-METRIC TALLY: VERU 3
— EDSA 0
■ METRIC PARITY
LAST: $2.23 (-1.76%) • MKT CAP: $38.0M
forward-pe
—
LAST: $2.70 (+5.47%) • MKT CAP: $36.5M
forward-pe
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VERU VS. EDSA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VERU | EDSA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -20.08% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 1/9 | +1.00 | VERU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.2 | 32.8 | +7.44 | VERU | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $38.0M | $36.5M | $1.6M | VERU | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VERU REV | EDSA REV | VERU GROSS % | EDSA GROSS % | VERU FCF | EDSA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$30.0M | -$7.3M |
| FY 2024 | $16.9M | $0 | 34.7% | — | -$21.8M | -$4.9M |
| FY 2023 | $16.3M | $0 | — | — | -$88.0M | -$6.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VERU // BETA —
EDSA // BETA —